Review of NICE Technology Appraisal Guidance No. 117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

The Institute was proposing that TA117 should be moved to the static list as none of the evidence which has come to light since the guidance was published would lead to a change in the original recommendations.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, TA117 will be moved to the static list. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

June 2013